Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

FDA Clears Varian Medical's Two Products - Quick Facts

RELATED NEWS
Trade VAR now with 

Varian Medical Systems (VAR: Quote) Thursday said it has received an FDA 510(k) clearance for the latest version of its Vitesse real time planning for HDR brachytherapy. This is used to plan and perform high-dose-rate or HDR, ultrasound-guided brachytherapy treatments for prostate cancer.

Tim Clark, marketing manager for Varian BrachyTherapy, said, "This version of Vitesse reduces the number and complexity of steps involved in planning and completing a treatment. It eliminates the need for a data transfer to another software program, and avoids moving the patient to a CT scanner for images in the middle of the procedure.''

According to him, most clinicians will see a reduction in the amount of time needed to complete these treatments, often by as much as an hour and a half.

Separately, the company said the regulator also cleared its Edge radiosurgery suite, a new dedicated system for performing advanced radiosurgery using innovative real-time tumor tracking and motion management technologies.

According to the company, this enables fast, accurate delivery of stereotactic radiosurgery for treating lesions, tumors, and conditions anywhere in the body where radiotherapy is indicated, including tumors of the lung, prostate, spine and brain.

Register
To receive FREE breaking news email alerts for Varian Medical Systems and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.